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Abstract
Background: We investigated the occurrence and clinical significance of mucin expression in ampullary
adenocarcinoma.
Methods: We retrospectively analyzed clinical, pathological, and survival data from 74 ampullary adenocarcinoma
patients who received radical operation from January 2004 to November 2006.
Results: The tumors were located in the lower end of the common bile duct (46%), papillary duodenum (42%),
and ampullary duodenum (12%), and expressed MUC1 (72%), MUC2 (20%), MUC5AC (43%), and MUC6 (27%).
Expression of MUC1 was associated with tumor differentiation (OR: 4.71, 95% CI: 1.26, 17.66, P = 0.021). Expression
of MUC5AC was associated with age (OR: 1.07, 95% CI: 1.11, 1.14, P = 0.026) and less vessel invasion(OR: 0.14, 95%
CI: 0.03, 0.72, P = 0.019). The survival rates were not significantly different when patients had or had no expression
of MUC1, MUC2, MUC5AC, or MUC6 in tumor. Patients with tumors positive for MUC5AC in the papillary
duodenum had worse survival than those with tumors negative for MUC5AC (P = 0.044).
Conclusions: Expression of MUC1 was high (72%) in ampullary adenocarcinoma, while expressions of MUC2,
MUC5AC, and MUC6 were lower. Mucins are useful markers to diagnose and identify ampullary adenocarcinoma,
particularly in determining the degree of malignancy of ampullary adenocarcinoma.
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Background
Ampullary adenocarcinoma, which occurs in the area of
the head of the pancreas, comprises about 5-6% of can-
cers arising in that region [1]. Cancer of the ampulla is
a rare disease, occurring in less than one per 100,000
cases [2]. Because even small lesions in the ampulla can
obstruct the bile duct, early jaundice and early presenta-
tion occurs, which may lead to the overall five-year sur-
vival of 30% to 50%, which is better than that of other
periampullary neoplasms. Two major histological types
of these tumors have been recognized, which are an
intestinal type that arises from intestinal mucosa of the
papilla, and a biliopancreatic type that arises from the
biliopancreatic ductal epithelium [3]. These two types
have been separated by immunohistochemically analyz-
ing their expression of MUC2 [4], which is one of a
class of macromolecular glycoproteins with a complex
glycosylation structure. The histological differentiation is
a key factor in the prognosis of ampullary cancer [2].
The intestinal subtype is negative for MUC1 and the
biliopancreatic subtype is negative for MUC2 [2,5-7].
The differing expression of mucins in ampullary adeno-
carcinomas is attributed to the development of histogen-
etically differing carcinomas that come from the
intestinal or the pancreaticobiliary mucosa.
Mucins are high molecular weight glycoproteins that
are distributed on the cell surface, where they serve as
selective barriers, and participate in intercellular recog-
nition, adhesion, and signal transduction [8]. Mucins are
widely distributed in gastrointestinal tumors and normal
t i s s u e s ,o fw h i c hM U C 1 ,M U C 2 ,M U C 5 A C ,a n dM U C 6
are more important [9]. Abnormal mucin expression is
associated with tumors, where mucins play an important
role in occurrence and development [8]. Various mucins
express differently in tumors and normal tissues. For
example, normal pancreatic tissue mainly expresses
MUC1 and MUC6, while ampullary adenocarcinoma
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MUC6 and MUC2 [3,11,12]. Combined detection of
mucins has been used to diagnose and differentiate pan-
creatic ductal adenocarcinoma and ampullary adenocar-
cinoma [11-15].
Ampullary carcinoma prognosis is currently based on
stage, lymph node metastases, negative surgical margins,
and presence of microsatellite instability, with stage
being the only independent prognostic factor, and
mucin expression not predicting survival [3]. Circulating
antibodies to MUC1 are associated with a favorable
prognosis in pancreatic cancer [16], while expression of
MUC1 indicates a poor prognosis in pancreatobiliary
pancreatic head tumors [17]. The expression of
MUC5AC is associated with better prognosis for ampul-
lary carcinoma [18], and with better survival of invasive
ductal carcinoma of the pancreas [19].
This study explored the relationships between diagno-
sis, identification, and survival of ampullary adenocarci-
noma and the expressions of MUC1, MUC2, MUC5AC,
and MUC6. The positive expression of MUC1 was the
highest of the four mucins investigated, and the expres-
sions of MUC1 and MUC5AC were associated with
levels of tumor aggressiveness. Patients with tumors




This retrospective study enrolled 74 patients from Qilu
Hospital of Shandong University from January 2004 to
November 2006 who were pathologically diagnosed with
ampullary adenocarcinoma, received radical operation,
and had complete clinical, pathological, and survival
data available. This study was approved by the ethical
review board of Qilu Hospital, and informed consent
was waived because of its retrospective nature.
Materials
The solution of 10% goat serum and primary antibody
against MUC6 were obtained from Boster Biotech
(Wuhan, Hubei, China). Primary antibodies against MUC1,
MUC2, and MUC5AC were obtained from the Laboratory
of Genetics, School of Life Sciences, Fudan University
(Shanghai, P.R. China). The goat anti-rabbit secondary anti-
body, the StreptAvidin-Biotin Complex (SABC) immuno-
histochemical assay kit, and the DAB chromogenic agent
were obtained from Boster Biotech. The Leica CM1900
microtome was from Wetzlar, Germany, and the BH2 light
microscope was from Olympus (Tokyo, Japan).
Methods
After surgery, the resected tumor sample was sent to the
department of pathology, where samples were fixed in
neural formaldehyde and preserved in paraffin until stu-
died, when they were sliced by microtome and then
deparaffinized by immersing sections twice for 12 min-
utes in xylene. The sections were hydrated by immersing
them twice for 10 minutes in absolute ethanol, then
twice for 5 minutes in 95% ethanol, then 5 minutes in
70% ethanol, and finally 5 minutes of rinsing with water.
Endogenous peroxidase was inactivated by immersing
sections in 3% hydrogen peroxide for 10 minutes and
then immersing the sections in PBS twice for 5 minutes
each time. Next, antigens were retrieved by twice
immersing the samples in citrate buffer, boiling the
immersed sections in a microwave oven for 10 seconds,
and allowing the sections to cool to room temperature.
Then, the sections were immersed in PBS twice for 5
minutes each time.
The sections were blocked by incubating them in 10%
g o a ts e r u ma t3 7 ° Cf o r3 0m i n u t e s ,a n dt h e ni n c u b a t e d
with primary MUC antibodies diluted 1:25 or with PBS
(control group) overnight at 4°C. Then, the sections
were rinsed twice in PBS for 5 minutes each time. Then,
the sections were incubated with goat anti-rabbit sec-
ondary antibodies diluted 1:100 at 37°C for 30 minutes
and then rinsed three times with PBS for 5 minutes.
The sections were incubated with SABC complex
diluted 1:100 at 37°C for 30 minutes, and then washed
three times in PBS for 5 minutes each wash. Color was
developed by adding diaminobenzidine (DAB), and,
when positive staining was observed under a light
microscope without nonspecific background staining,
the sections were washed with water for 5 minutes. The
sections were then counterstained by immersing them
in hematoxylin for 30 minutes and then washing them
with water for 5 to 10 minutes. Then, the sections were
dehydrated with 70% ethanol for two minutes, followed
by xylene for two minutes.
Gross changes were observed at low magnification of
10 x, and positive cells were counted at a high magnifi-
cation of 40 x. Positive cells were scored as: 0, negative;
1, 1% to 33%; 2, 34% to 67%; and 3, >67%. Positive cells
had brown granules in the nucleus and cytoplasm, and
staining intensity was scored as: 0, no staining; 1, light
yellow; 2, brownish yellow; and 3, brown in over half of
the observed area. The semi-quantitative analysis of cells
was the sum of both scores, with the final scores indi-
cating: 0, negative; 1 to 2, +; 3 to 4, ++; and 5 to 6, ++
+. The scoring was performed by two pathologists una-
ware of the study, and discrepancies were resolved by
consensus.
Statistical analysis
Because the cases were unevenly distributed among the
histological grades, we clustered them into two cate-
gories for statistical analysis: one category was
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cases, and the other was moderately (G2) and well dif-
ferentiated (G1) cases. Logistic regression analysis ana-
lyzed the odds ratio of significant factors associated with
patients with positive expression of each MUC family
(MUC1, MUC2, MUC5CA, and MUC6). Survival time
was measured from the time of operation to the time of
death or the last date of follow-up. The survival rates of
patients with positive and negative expression of MUC
family were compared through a Kaplan-Meier analysis
with log-rank test that measured survival over time. The
statistical assessments were all two-sided, and were con-
sidered significant if P < 0.05. Statistical analyses were
performed using SPSS 15.0 statistics software (SPSS Inc.,
Chicago, IL).
Results
Patient and tumor information
The ampullary adenocarcinoma patients in this study
included 46 men (62.2%) and 28 women (37.8%) whose
mean age was 60.4 ± 11.7 years (range 27 to 80 years)
(Table 1). The tumors were located in the lower end of
the common bile duct in 34 cases (46%), the papillary
duodenum in 31 cases (42%), and the ampullary duode-
num in 9 cases (12%). The mean tumor size was 2.08 ±
1.12 cm. Of the 74 patients, 71 underwent pancreato-
duodenectomy, one underwent pylorus-preserving pan-
creatoduodenectomy, and two underwent local tumor
resection. No perioperative deaths occurred. Five cases
of postoperative pancreatic leakage occurred, three of
gastroparesis, and six of delayed wound healing. All
complications were cured by conservative therapy.
All the patients were followed through June 30, 2008,
and 30 patients had died (41%). Most deaths were due
to tumor recurrence, liver metastasis, or extensive
metastases in the abdominal and pelvic cavity.
Expression of mucins in ampullary adenocarcinoma
Expression of MUC1 was detected in 38 of 53 cases
(72%), MUC2 in 10 of 50 cases (20%), MUC5AC in 22
of 51 cases (43%), and MUC6 in 13 of 48 cases (27%)
(Table 2). Most MUC1-positive tumors were poorly dif-
ferentiated or undifferentiated, but most MUC1-negative
tumors were well-differentiated or moderately differen-
tiated. MUC5AC-positive tumors seldom had blood ves-
sel invasion. Logistic regression analysis found that
expression of MUC1 was not significantly correlated
with TNM stage or presence of blood vessel and nerve
invasion of tumors but significant association was found
between MUC1 expression and tumors with middle or
high levels of differentiation(OR: 4.71, 95% CI: 1.26,
17.66, P = 0.021). MUC5AC expression was significantly
associated with age (OR: 1.07, 95% CI: 1.11, 1.14, P =
0.026), and negative correlations between MUC5AC
expression and vessel invasion (OR: 0.14, 95% C.I.: 0.03,
0.72, P = 0.019) was noticed. Expression of MUC2 and
MUC6 were not significantly correlated with any index
of tumors. In addition, there was no association between
the expression of each mucin gene and the location of
the tumors.
Mucin expression and survival of patients
Survival curves are shown in Figure 1. Survival rates
were not significantly affected by expression of MUC1,
MUC2, MUC5AC, or MUC6, though lack of MUC1 or
MUC5AC expression trended toward improved survival
compared to tumors that did express MUC1 or
MUC5AC (P = 0.078 for MUC1 and P = 0.058 for
MUC5AC) (Figure 1).
We compared survival curves based on the locations
of the tumors, which were in the lower end of the
common bile duct, in the papillary duodenum, or in
the ampullary duodenum (Figure 2). Among patients
with tumors in the papillary duodenum, those with
detectable MUC5AC had worse survival than those
without detectable MUC5AC (Figure 2, P =0 . 0 4 4 ) .N o
other significant associations between tumor location
Table 1 Patients’ demographics and baseline
characteristics
Variable No. (%) (N = 74)




Tumor size (cm) 2.08 ± 1.12
Location
Lower end of the common bile duct 34 (45.9)
Papillary duodenum 31 (41.9)
Ampullary duodenum 9 (12.2)
Tumor differentiation
No & Low 39 (52.7)
Middle & High 35 (47.3)
Tumor classification
T0 & T1 & T2 38 (51.4)








0 & I 28 (37.8)
II & III & IV 46 (62.2)
Vessel invasion 19 (25.7)
Nerve invasion 19 (25.7)
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expression of MUC2 in tumors in the lower end of the
common bile duct trended toward worse survival than
no MUC2 in tumors there (P = 0.061).
We further analyzed the survival curves of the 44
patients who had all four MUC isoforms tested. We did
not find significantly different survival rates for those
having the combinations of being positive for MCU5AC
and negative for MUC6, negative for MUC5AC and
MUC6, or negative for MUC5AC and positive for
MUC6AC (1+/2-/5+/6-, p = 0.668; 1+/2-/5-/6-, p =
0.131; 1+/2-/5-/6+, p = 0.073)(Figure 3).
Discussion
The expression of MUC1 occurred more frequently than
the other mucins studied, and it was associated with a
higher degree of differentiation of ampullary adenocarci-
noma. This result concurs with findings that MUC1 is
related to malignant behavior of pancreatic mucinous
cystic tumors [20]. Expression of MUC1 may affect
patient prognosis by inhibiting the formation of the E
cadherin and b-catenin complex, which would decrease
intercellular adhesion and promote the invasion and
metastasis of tumors [21], by enhancing tumor cell inva-
siveness through the involvement of MUC1 in the cell
Table 2 MUC gene expression and logistic regression analysis of associations between MUC family genes and clinical
characteristics
MUC1 (n = 53) MUC2 (n = 50) MUC5AC (n = 51) MUC6 (n = 48)
Variable No. (%)
Gene Expression
Positive 38 (71.7) 10 (20.0) 22 (43.1) 13 (27.1)
Negative 15 (28.3) 40 (80.0) 29 (56.9) 35 (72.9)
OR (95% C.I.)
Age 1.02 (0.97, 1.07) 1.01 (0.95, 1.07) 1.07 (1.11, 1.14)* 1.04 (0.97, 1.10)
Gender
Female 1.00 1.00 1.00 1.00
Male 2.45 (0.73, 8.42) 2.96 (0.56, 15.73) 0.88 (0.28, 2.74) 2.22 (0.52, 9.54)
Tumor size 0.90 (0.50, 1.65) 0.72 (0.32, 1.58) 1.60 (0.86, 2.97) 0.50 (0.22, 1.11)
Location
Lower end of the common bile duct 1.00 1.00 1.00
Ampullary duodenum 0.22 (0.02, 1.93) - 1.08 (0.13, 8.80) -
Papillary duodenum 0.35 (0.10, 1.31) 1.25 (0.31, 5.09) 0.58 (0.18, 1.91) 1.50 (0.41, 5.51)
Tumor differentiation
No & Low 1.00 1.00 1.00 1.00
Middle & High 4.71 (1.26, 17.66)* 0.91 (0.22, 3.62) 1.55 (0.51, 4.74) 0.47 (0.13, 1.72)
Tumor classification
T0 & T1 & T2 1.00 1.00 1.00 1.00
T3 & T4 1.50 (0.45, 5.05) 0.43 (0.10, 1.90) 2.05 (0.66, 6.31) 1.56 (0.43, 5.59)
Node classification
N0 1.00 1.00 1.00 1.00
N1 1.09 (0.32, 3.69) 1.00 (0.23, 4.11) 1.90 (0.61, 5.90) 0.36 (0.08, 1.52)
Distant metastasis
M0 1.00 1.00 1.00 1.00
M1 0.38 (0.02, 6.47) - 1.33 (0.80, 22.57) -
TNM stage
0 & I 1.00 1.00 1.00 1.00
II & III & IV 1.28 (0.37, 4.39) 0.54 (0.13, 2.18) 1.88 (0.57, 6.21) 0.69 (0.19, 2.50)
Vessel invasion,
No 1.00 1.00 1.00 1.00
Yes 1.63 (0.38, 6.92) 1.13 (0.25, 5.17) 0.14 (0.03, 0.72)* 0.46 (0.09,
Nerve invasion
No 1.00 1.00 1.00 1.00
Yes 1.63 (0.38, 6.92) 1.29 (0.68, 5.94) 3.32 (0.92, 12.01) 0.36, 6.19)
* indicates statistical significance where P < 0.05.
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let-derived growth factor b [22], and by increasing the
resistance of tumor cells to cytotoxic chemotherapeutics
like 5FU [23].
The expression of MUC5AC was associated with worse
survival among patients who had tumors in the papillary
duodenum than those with tumors with undetectable
MUC5AC. Additionally, MUC5AC expression was asso-
ciated with patient age and negatively correlated with
vessel invasion. These results are in agreement with find-
ings that MUC5AC expression levels decreased as the
malignancy of gallbladder tumor [24] and gastric signet
ring cell carcinoma [25] increased; colon cancer negative
for MUC5AC had more tumor recurrence, metastasis,
and worse prognosis than those positive for MUC5AC
[26]; and pancreatic ductal adenocarcinoma positive for
MUC5AC expression was correlated with better prog-
nosis [19] and less vascular invasion. In a separate study,
we found that MUC5AC was significantly associated with
TNM stage of pancreatic ductal adenocarcinoma and its
vascular invasion than those negative for MUC5AC
expression (unpublished data). The expression of
MUC5AC may be related to the vascular invasiveness of
tumors because MUC5AC is a gastric-type secretory
mucin that can enhance intercellular adhesion by pro-
moting the formation of a high-viscosity gel [27].
Our study has explored the connection between peri-
ampullary tumors and mucins, which is slightly different
Figure 1 Survival curves of the expression of MUC family genes. Kaplan-Meier curves analyze the relationships between survival and
expression of MUC1 (A), MUC2 (B), MUC5AC (C), and MUC6 (D), where those patients with tumors negative for the gene expression are shown
with solid lines, and those with tumors positive for the gene expression are shown with dashed lines. The open circles (○) indicate censored
patients with tumors negative for the gene expression, and the open squares (□) indicate censored patients with tumors positive for the gene
expression.
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Page 5 of 8Figure 2 Survival curves of the expression of MUC family genes by different tumor location. Kaplan Meier curves analyze the relationships
between survival and location of tumors for MUC1 (A), MUC2 (B), MUC5AC (C), and MUC6 (D), for tumors located in (1) the lower end of the
common bile duct, (2) the papillary duodenum, and (3) the ampullary duodenum. The solid lines indicate tumors that were negative for the
MUC gene expression, the dashed lines indicate tumors that were positive for the MUC gene expression, the open circles (○) indicate censored
patients with tumors negative for the gene expression, and the open square (□) indicate censored patients with tumors positive for the gene
expression.
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Page 6 of 8Figure 3 Survival curves of the expression of combinations of Mucins (n = 44). Kaplan-Meier curves analyze the relationships between survival and combinations of expression of MUC
genes, including the combination of (A) MUC1 +, MUC2 -, MUC5AC +, and MUC6 -; (B) MUC1 +, MUC2 -, MUC5AC -, and MUC6 -; and (C) MUC1 +, MUC2 -, MUC5AC -, and MUC6+ indicated by
































































































8than the connection between pancreatic cancer and
mucins. Our institution routinely stains some gastroin-
testinal tumors for mucins. Further understanding the
expression and mechanisms of mucins may help to
improve survival of periampullary tumors. Our study is
limited by the small number of cases studied and by the
incomplete analyses of the tumors for the four MUC
genes studied. We independently analyzed the expres-
sion of each MUC gene by logistical regression analysis
(Table 2), but only a few patients had more than one
MUC gene expressed, which was too small of a sample
to statistically analyze. Th es m a l ls a m p l es i z ed i dn o t
allow us to find any statistical significance as we sought
to test the hypothesis that mucin expression patterns
may differentiate the prognosis for a distinct tumor type
or stage. Future work will benefit from larger numbers
of patients studied and more complete analyses of MUC
genes.
In summary, ampullary adenocarcinoma patients may
benefit from detecting the composition of mucins in
resected tumor specimens, since this will facilitate both
diagnosis and differential diagnosis. Mucin composition
analysis may also help to determine the degree of malig-
nancy of ampullary adenocarcinoma.
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